Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-068454

Executive VP, Head of R&D gave up 12,607 shares (to pay taxes)

  • Executive VP, Head of R&D acquired 26,667 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Ho Tony W Executive VP, Head of R&D 2021-12-03 Option exercise +26,667 64,971 D: show line 1 in the form
Ho Tony W Executive VP, Head of R&D 2021-12-06 Shares withheld for taxes −12,607 $69.17 $872,026 52,364 D: show line 2 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Ho Tony W Executive VP, Head of R&D 2021-12-03 Option exercise · Restricted Stock Units +26,667 13,333 D: show line 3 in the form
Loading xslF345X03/doc4.xml…